Adolore BioTherapeutics, Inc., (”Adolore” or the “Company”), a biotechnology company developing transformational opioid-free intracellularly-delivered treatments for chronic pain, today announced that ...

A new study by Stewart Tepper and team showed that monthly 140 mg erenumab injections in individuals with non-opioid chronic ...

LAHORE: Different essential and life-saving drugs have disappeared from the market, putting the health and even ...

Former Baltimore Health Commissioner and Maryland Health Secretary Joshua Sharfstein testified at the city’s trial against ...

DELRAY BEACH, FL / ACCESSWIRE / September 24, 2024 / Adolore BioTherapeutics, Inc., ("Adolore" or the "Company"), a biotechnology company developing transformational opioid-free intracellularly-delive ...

In a world mired by emerging tensions and uncertainties, what could be the way out? Kairat Sarybay (Sarybay), ...

Two employees received stock options to purchase an aggregate of 5,000 shares of Pacira common stock and 17 employees received restricted stock units for an aggregate of 30,000 shares of Pacira common ...

The global chronic pain market is set to experience robust growth, with projections estimating it will reach an impressive ...

In patients starting opioid treatment for noncancer pain, being prescribed more opioids, getting repeated or refillable prescriptions, and being prescribed long-acting opioids were the top factors ...

The National Agency for Food, Drugs Administration, and Control (NAFDAC) has destroyed substandard products worth N43 billion ...